Most Liquid ARCA Pharmaceutical Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1TAK Takeda Pharmaceutical Co
533.53 B
(0.12)
 0.89 
(0.10)
2NVO Novo Nordisk AS
37.47 B
(0.23)
 1.81 
(0.41)
3MRK Merck Company
12.69 B
(0.17)
 1.20 
(0.20)
4ABBV AbbVie Inc
11.88 B
(0.04)
 2.08 
(0.07)
5BMY Bristol Myers Squibb
9.12 B
 0.15 
 1.98 
 0.30 
6SNY Sanofi ADR
6.9 B
(0.18)
 1.21 
(0.22)
7JNJ Johnson Johnson
5.37 B
(0.11)
 0.78 
(0.09)
8NVS Novartis AG ADR
4.64 B
(0.22)
 0.98 
(0.22)
9AZN AstraZeneca PLC ADR
4.52 B
(0.27)
 1.52 
(0.40)
10GSK GlaxoSmithKline PLC ADR
3.72 B
(0.24)
 1.46 
(0.36)
11ZTS Zoetis Inc
3.58 B
(0.04)
 1.29 
(0.05)
12RDY Dr Reddys Laboratories
2.93 B
(0.20)
 1.31 
(0.26)
13PFE Pfizer Inc
2.85 B
(0.10)
 1.43 
(0.15)
14TEVA Teva Pharma Industries
2.22 B
(0.10)
 1.78 
(0.19)
15LLY Eli Lilly and
2.07 B
(0.15)
 1.89 
(0.29)
16RPRX Royalty Pharma Plc
1.47 B
(0.12)
 0.99 
(0.12)
17JAZZ Jazz Pharmaceuticals PLC
899.36 M
 0.05 
 2.07 
 0.11 
18VTRS Viatris
741.9 M
 0.07 
 2.28 
 0.17 
19OGN Organon Co
706 M
(0.23)
 2.04 
(0.47)
20ALKS Alkermes Plc
580.97 M
 0.03 
 2.35 
 0.07 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).